#USA #Facet Life Sciences #Phoenixville #XCancer #TheranosticTrials

Facet Life Sciences and XCancer Join Forces

In a significant move aimed at transforming cancer care, Facet Life Sciences has announced a vital partnership with XCancer, a notable player in theranostic clinical research. This collaboration is designed to fast-track the development and approval of state-of-the-art radiopharmaceutical therapies dedicated to oncology.

Accelerating Access to Innovation

The partnership leverages Facet's extensive regulatory and developmental expertise, especially in diagnostic and therapeutic radiopharmaceuticals, alongside XCancer’s advanced clinical trial network. This synergy is expected to streamline the intricate process of bringing precision diagnostic and therapeutic solutions to patients more efficiently. As a result, both organizations aim to reduce the barriers that traditionally impede swift access to cutting-edge cancer treatments.

Empowering Clinical Trials

Facet Life Sciences is now featured prominently on XCancer's flagship platform, TheranosticTrials.Org. This innovative website serves as a central hub where researchers, clinicians, sponsors, and patient advocates can connect. The platform seeks to foster awareness, share vital expertise, and enhance global access to cancer innovations, showcasing the collaborative nature of modern clinical research.

Dr. Lisa Jenkins VanLuvanee, COO of Facet Life Sciences, expressed, "At Facet, our mission has always encompassed the principles of delivering innovative therapeutic solutions to patients certainly and efficiently. Partnering with XCancer aligns perfectly with our goals, as it merges our regulatory strengths with their unique clinical research methodologies. We are positioned to have a real impact on the advancement of theranostic therapies and improving patient access to precision medicine."

A Vision for the Future

XCancer's CEO, Dr. Luke Nordquist, echoed these sentiments, stating, "Facet's established regulatory expertise complements our strategic vision splendidly. We are constructing an ecosystem intended to eliminate obstacles for sponsors, accelerate clinical trial activations, and ultimately introduce transformative radiopharmaceutical therapies to patients who are in dire need. Our partnership symbolizes the very essence of theranostics — integrating diagnostics and therapeutics to provide personalized cancer treatment options."

The combination of diagnostic imaging and targeted therapy epitomizes one of the most promising areas of growth in oncology. The collaboration between Facet and XCancer is set to simplify the regulatory and development complexities that have historically delayed the availability of transformative therapies for those battling cancer.

About Facet Life Sciences

As an employee-owned enterprise, Facet Life Sciences is committed to aiding life sciences organizations throughout every developmental phase. The company offers unmatched expertise in regulatory planning, drug development, FDA submissions, strategic analytics, and overall commercialization support. It has a pronounced focus on the realms of diagnostic, theranostic pharmaceuticals, oncology, and rare disease programming. For more information, visit www.FacetLifeSciences.com.

About XCancer

Founded with the goal of innovating cancer clinical research, XCancer is based in Omaha, Nebraska and stands out as a global authority in theranostic evaluation. This organization, under Dr. Nordquist's guidance, boasts one of the largest community-based research networks in the nation and is actively conducting numerous Phase I-III clinical trials, demonstrating a commitment to ground-breaking research in radiopharmaceuticals and precision oncology. For further details, explore www.XCancer.com.

About TheranosticTrials.Org

The TheranosticTrials.Org platform aims to propel the field of Theranostics by advancing collaboration, awareness, and access to education around the integration of diagnostics with therapeutics. This initiative bridges the gap between researchers, clinicians, sponsors, and advocates, promoting visibility into clinical trials and encouraging equitable access to groundbreaking cancer treatments. Explore more at www.TheranosticTrials.org.